Cargando…

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

INTRODUCTION: Hemophilia A treatment involves replacing the deficient coagulation factor VIII. This process may involve multiple steps that might create a barrier to adherence. A new dual-chamber syringe (DCS; FuseNGo(®)) was recently introduced with the aim of simplifying reconstitution. AIM: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cimino, Ernesto, Linari, Silvia, Malerba, Mara, Halimeh, Susan, Biondo, Francesca, Westfeld, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270299/ https://www.ncbi.nlm.nih.gov/pubmed/25525348 http://dx.doi.org/10.2147/PPA.S64709

Ejemplares similares

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries [Corrigendum]
Publicado: (2015)

Patient preference for needleless factor VIII reconstitution device: the Italian experience
por: Musso, Roberto, et al.
Publicado: (2010)

Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution
por: Shim, Ye Jee, et al.
Publicado: (2014)

Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)
por: Ueda, Hitoshi, et al.
Publicado: (2020)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII
por: Sayyadipour, Fatemeh, et al.
Publicado: (2020)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2016)

EASE Guidelines for Authors and Translators of Scientific Articles to be Published in English: European Association of Science Editors (EASE)
Publicado: (2011)

Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes
por: Dalm, Daniela, et al.
Publicado: (2015)

Human coagulation factor VIII domain-specific recombinant polypeptide expression
por: Choi, Su Jin, et al.
Publicado: (2015)

Study on Coagulation Factor VIII and Fibrinogen Levels in Patients with Thyroid Disorders
por: Thoyyib, Muhammed, et al.
Publicado: (2018)

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
por: Firrman, Jenni, et al.
Publicado: (2020)

Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease
por: Pradhan-Sundd, Tirthadipa, et al.
Publicado: (2021)

Characterization and visualization of murine coagulation factor VIII-producing cells in vivo
por: Hayakawa, Morisada, et al.
Publicado: (2021)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials
por: Riley, John H, et al.
Publicado: (2016)

Immune reconstitution inflammatory syndrome in a unique clinical scenario
por: Anubhav, G., et al.
Publicado: (2010)

Detection of Fibrinogen and Coagulation Factor VIII in Plasma by a Quartz Crystal Microbalance Biosensor
por: Yao, Chunyan, et al.
Publicado: (2013)

Mutations in Coagulation Factor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma
por: Ping, Zheng, et al.
Publicado: (2017)

Protein residue network analysis reveals fundamental properties of the human coagulation factor VIII
por: Lopes, Tiago J. S., et al.
Publicado: (2021)

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
por: Andre, Anthony D, et al.
Publicado: (2017)

Limited Promiscuity of HLA-DRB1 Presented Peptides Derived of Blood Coagulation Factor VIII
por: van Haren, Simon D., et al.
Publicado: (2013)

Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat
por: Rasmussen, Caroline E., et al.
Publicado: (2017)

Six cases of autoimmune acquired coagulation factor VIII deficiency: Single center experience in Japan
por: Konishi, Akiko, et al.
Publicado: (2020)

Therapeutic Effects of Kefir Peptides on Hemophilia-Induced Osteoporosis in Mice With Deficient Coagulation Factor VIII
por: Yen, Chih-Ching, et al.
Publicado: (2022)

No longer at ease
por: Achebe, Chinua

Easing pain
por: Bernard, Carrie
Publicado: (2023)

The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics
por: Casademunt, Elisabeth, et al.
Publicado: (2012)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Maturation of coagulation factor IX during Xase formation as deduced using factor VIII‐derived peptides
por: Fang, Han, et al.
Publicado: (2019)

Effects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity
por: Zhao, Ying, et al.
Publicado: (2017)

Coagulation factor VIII, white matter hyperintensities and cognitive function: Results from the Cardiovascular Health Study
por: Rohmann, Jessica L., et al.
Publicado: (2020)

An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review
por: Zadeh Mehrizi, Tahereh, et al.
Publicado: (2021)

Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension
por: Myllylahti, Lasse, et al.
Publicado: (2023)

Patient preferences for characteristics of antiretroviral therapies: results from five European countries
por: Gazzard, Brian, et al.
Publicado: (2014)

Minimising treatment-associated risks in systemic cancer therapy
por: Jaehde, Ulrich, et al.
Publicado: (2007)

Physician preferences associated with powered intraosseous access systems: Safety features, reliability, and ease of use
por: Little, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lf2sq2h5op2e874vn9bjlrrshn